← All trials
NCT05499234
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2022
- Primary completion
- Sep 15, 2022
- Completion date
- Nov 30, 2022
- First posted
- Aug 12, 2022
- Last posted
- Aug 12, 2022
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Istanbul Medipol UniversityLead sponsor
- Istanbul Medipol UniversityOverall official - principal investigator
- Istanbul Medipol UniversityReponsible party - principal investigator
- Istanbul Medipol UniversityStudy chair
- Istanbul Medipol UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.